Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Dr Karan Rajan, an NHS surgeon and University of Sunderland lecturer, has shared his thoughts on 'menstrual blood-derived ...

CUNY scientists made a key Alzheimer's disease breakthrough, identifying a vital mechanism in the brain’s immune cells that ...

TAMPA, Fla. - Every year, about 500,000 people are diagnosed with Alzheimer's disease. For many, the holidays are a key time ...

It should come as no surprise that Alzheimer’s has touched the lives of two individuals designated by President-elect Donald ...

Frankl believed that life can be made meaningful in a three-fold way: through what we give (in terms of creative work), from ...

Early research links the human cytomegalovirus, a type of herpes virus found in the gut, to the development of Alzheimer’s ...

The daily medication, called hydromethylthionine mesylate (HMTM), was developed by British firm TauRX in Aberdeen ...

ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Alzheimer's Disease.

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.